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Background: The development of a protective vaccine against canine visceral leishmaniasis (CVL) is an alternative
approach for interrupting the domestic cycle of Leishmania infantum. Given the importance of sand fly salivary
proteins as potent immunogens obligatorily co-deposited during transmission of Leishmania parasites, their
inclusion in an anti-Leishmania vaccine has been investigated in the last few decades. In this context, we previously
immunized dogs with a vaccine composed of L. braziliensis antigens plus saponin as the adjuvant and sand fly
salivary gland extract (LBSapSal vaccine). This vaccine elicited an increase in both anti-saliva and anti-Leishmania IgG
isotypes, higher counts of specific circulating CD8+ T cells, and high NO production.
Methods: We investigated the immunogenicity and protective effect of LBSapSal vaccination after intradermal
challenge with 1 × 107 late-log-phase L. infantum promastigotes in the presence of sand fly saliva of Lutzomyia
longipalpis. The dogs were followed for up to 885 days after challenge.
Results: The LBSapSal vaccine presents extensive antigenic diversity with persistent humoral and cellular immune
responses, indicating resistance against CVL is triggered by high levels of total IgG and its subtypes (IgG1 and IgG2);
expansion of circulating CD5+, CD4+, and CD8+ T lymphocytes and is Leishmania-specific; and reduction of splenic
parasite load.
Conclusions: These results encourage further study of vaccine strategies addressing Leishmania antigens in
combination with proteins present in the saliva of the vector.
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Dogs are the most important domestic reservoir of Leish-
mania infantum, the protozoan parasite causing visceral
leishmaniasis (VL), and represent the major source of con-
tagion for the vector, increasing the risk for human infec-
tion [1]. Treatment of infected dogs is not an effective
strategy because relapses are frequent, and dogs quickly be-
come infectious again [2]. In this context, a vaccine would
be an important tool in the control of canine visceral leish-
maniasis (CVL) and would also dramatically decrease the
infection pressure of L. infantum for humans [3].
Significant efforts are being made by several groups to
develop a vaccine against CVL [4-18]. Given their wide
spectrum of antigenicity, cost, and safety, the first gen-
eration vaccines that composed of crude antigens also
represent an excellent tool for immunoprophylaxis
[10,11,13-15,19]. In phase I and II clinical trials, Mayrink
et al. [10], demonstrated enhanced lymphocyte prolifera-
tion and significant protection (90%) against experimental
infection with L. infantum in dogs that had received
ultrasound-disrupted, merthiolated promastigotes of L.
braziliensis with Bacillus Calmete-Guerin (BCG). Strong
cellular proliferation in response to soluble Leishmania
antigens has also been reported in dogs vaccinated with
autoclaved L. major promastigotes plus BCG as the adju-
vant [11]. Moreover, in a double-blind randomized efficacy
field trial, a single dose of a vaccine composed of alum-
precipitated autoclaved L. major vaccine against CVL
mixed with BCG was shown to be safe and decreased the
incidence of the CVL from 12% to 3.7%, which is equiva-
lent to a 69.3% efficacy rate [20].
In the last few decades, the incorporation of salivary
proteins of phlebotomines has been widely used in experi-
mental challenge studies, or in seeking potential targets
for vaccine development against Leishmania infection;
such proteins have even been a part of vaccine compos-
ition as an adjuvant or co-adjuvant [14,21-29]. Gomes
et al. [28] showed that hamsters immunized with DNA
plasmid coding LJM19 from Lutzomyia longipalpis were
protected against a challenge with L. infantum plus Lu.
longipalpis salivary gland sonicate [28]. Collin et al. [29],
working with dogs immunized with saliva recombinant
proteins of Lu. longipalpis (LJL143 and LJM17) and chal-
lenged with uninfected or infected sandflies, observed a
cellular immune response at the site of the bite charac-
terized by lymphocytic infiltration and expression of
interferon-γ or interleukin-12 [29]. These results suggest
that the use of Lu. longipalpis saliva proteins could be a
good strategy in developing an anti-CVL vaccine in dogs. In
this context, previous studies in dogs conducted by our
group used a first generation vaccine composed of L. brazi-
liensis antigens plus saponin as an adjuvant and sand fly
salivary gland extract (SGE) (LBSapSal vaccine). The
immunization elicited increases in the anti-saliva and anti-Leishmania IgG isotypes, higher counts of circulating and
specific T CD8+, and high NO production after immunization
[14]. The current study included an analysis of the immuno-
genicity and a parasitological investigation of dogs immu-
nized with LBSapSal vaccine. The dogs were evaluated for
up to 885 days after challenge by intradermal inoculation
using L. infantum promastigotes plus Lu. longipalpis SGE.
Methods
The study protocol was approved by the Ethical Committee
for the Use of Experimental Animals at the Universidade
Federal de Ouro Preto, Minas Gerais, Brazil.
Sand flies and salivary gland extracts
Closed colonies of Lu. longipalpis were maintained at
25°C and 60%–80% relative humidity according to a
published protocol [30]. Sand fly SGE was prepared
using the method of Cavalcante et al. [31] in which the
acini of salivary glands of 4-day-old, mated, but non–
blood-fed female sand flies were dissected in 0.8% un-
buffered saline, broken by sonication for 10 s, and cen-
trifuged at 10,000 × g for 2 min. The supernatant was
collected and stored at −70°C prior use.
Study animals, vaccination, and experimental challenge
In this study, we used the LBSapSal vaccine as previously
described by Giunchetti et al. [14]. Twenty male and fe-
male mongrel dogs were born and reared in the kennels of
the Animal Science Center, Universidade Federal de Ouro
Preto, Ouro Preto, Minas Gerais, Brazil. The dogs were
treated by 7 months of age with an anthelmintic and vac-
cinated against rabies (Tecpar, Curitiba-PR, Brazil), canine
distemper, type 2 adenovirus, coronavirus, parainfluenza,
parvovirus, and leptospira (Vanguard® HTLP 5/CV-L; Pfi-
zer Animal Health, New York, NY, USA). The absence of
specific anti-Leishmania antibodies was confirmed by
indirect fluorescence immunoassay and enzyme-linked
immunosorbent assay (ELISA) tests. Ouro Preto city is
considered a non-endemic area for visceral leishmaniasis
in Brazil. Besides negative serology, other additional effect-
ive approaches were performed aiming to rule out Leish-
mania infection such as spraying the kennels of UFOP
with pyrethroid insecticide and protecting all extension of
the kennels with an appropriate and security stainless steel
wire mesh to block the access of phlebotomines.
At the beginning of the experiments the dogs were ap-
proximately the same age (210 ± 45 days) and had similar
weights (15 ± 5 kilograms) and were randomly chosen
from a set with approximately the same number of males
and females and divided into four experimental groups: (i)
the control group C (n = 5) that received 1 mL of sterile
0.9% saline; (ii) the Sal group (n = 5) that received SGE pre-
pared from five acini of salivary glands of Lu. longipalpis in
1 mL of sterile 0.9% saline; (iii) the LBSal group (n = 5) that
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SGE (as above) in 1 mL sterile 0.9% saline; and (iv) the
LBSapSal group (n = 5) that received 600 μg of L. brazilien-
sis promastigote protein plus 1 mg of saponin together
with SGE in 1 mL of sterile 0.9% saline. Each group re-
ceived three subcutaneous injections in the right flank at
intervals of 4 weeks. Three and a half months (105 days)
after the last vaccine dose, the dogs were challenged via
intradermal injection in the right ear, with 1 × 107 late-
log-phase L. infantum promastigotes (MHOM/BR/1972/
BH46) plus SGE obtained from two acini of Lu. longipalpis
salivary glands [32-34]. Dogs were followed for 885 days
after challenge. Evaluation of the humoral and cellular im-
mune response was performed before challenge (Tbc; i.e.
85 days before experimental challenge) and 20, 90, 274,
435, 541 and 885 days after challenge (dac). The dogs were
euthanized in 885 dac and the spleen was collected to
evaluate the parasite load.
Blood sample collection
Peripheral blood (5 mL) was collected from the jugular
vein of each dog and transferred to tubes containing
EDTA as anticoagulant. The absolute count of lympho-
cytes in each sample was obtained using a BC-2800 VET
auto hematology analyzer (Mindray, China). Blood sam-
ples were stored at room temperature for up to 12 h
prior to processing.
Humoral immune response
The humoral immune response was evaluated by using
soluble lysate of L. infantum antigen (MHOM/BR/1972/
BH46) (SLiA) according to conventional enzyme-linked
immunosorbent assay (ELISA) as previously described by
Reis et al. [35] and Giunchetti et al. [13]. Briefly the SLiA
was coated onto 96-well microplates (MaxiSorp™, Nalge
Nunc Intl., Rochester, NY, USA) at a concentration of
10 μg/well, the serum samples were added at 1:80 dilution,
the wells were washed, and peroxidase-conjugated goat
anti-dog IgG1 or sheep anti-dog IgG and IgG2 (Bethyl
Laboratories Inc., Montgomery, TX, USA) were added at
dilutions of 1:1000, 1:8000, and 1:16,000, respectively. The
wells were then washed, substrate and chromogen (o-
phenylenediamine; Sigma–Aldrich Co., St. Louis, MO,
USA) were added, and the absorbance was read at 492 nm
on a Multiskan® MCC 340 (Labsystems, Helsinki, Finland)
automatic microplate reader.
In vitro assays
For in vitro evaluation, peripheral blood mononuclear
cells (PBMCs) were isolated from 20 mL of heparinised
blood under 10 mL of Ficoll–Hypaque density gradient
(Histopaque® 1.077; Sigma Chemical Co.), and centri-
fuged at 450 × g for 40 min at room temperature. The
PBMCs were resuspended in Gibco RPMI1640 medium,homogenized, washed twice with RPMI 1640, centri-
fuged at 450 × g for 10 min at room temperature, ho-
mogenized, and resuspended in RPMI 1640 at 107 cells/
mL. Briefly, for the mitogenic stimulus assays, 25 μL ali-
quots of PBMCs (2.5 × 105 cells/well) were added to trip-
licate wells together with 25 μL of phytohemagglutinin
(2.5 μg/mL; Sigma-Aldrich Chemie GmbH, Taufkirchen,
Germany). Incubations were carried out in a humidified
5% CO2 atmosphere at 37°C for 3 days (mitogenic-stimu-
lated cultures) or 5 days (antigenic-stimulated cultures).
To investigate the immunophenotypic features, PBMCs
were cultured in 48-well flat-bottomed tissue culture
plates (Costar, Cambridge, MA, USA) containing 650 μL
of supplemented RPMI medium/well. Fifty microliters of
PBMCs (5.0 × 105 cells/well) was added to triplicate wells
together with 100 μL of vaccine soluble antigen (VSA)
(25 μg/mL) or 100 μL of SLcA (25 μg/mL). Incubation
was carried out in a humidified 5% CO2 atmosphere at
37°C for 5 days, after which the PBMCs were removed for
immunophenotyping according to Giunchetti et al. [13].
Immunophenotyping and flow cytometry
Unlabeled canine monoclonal antibodies (mAbs) against
CD5 (rat-IgG2a: clone YKIX322.3), CD4 (rat-IgG2a: clone
YKIX302.9), and CD8 (rat-IgG1: clone YCATE55.9), all
purchased from Serotec (USA), were used in an indirect
immunofluorescence procedure in which pooled normal
rat serum (diluted 1:6000) was employed as the isotypic
control, and fluorescein isothiocyanate (FITC)-labelled
IgG sheep anti-rat polyclonal antibody was used as the
secondary antibody.
Briefly, microplate assays for immunophenotyping ca-
nine whole blood leukocytes in both fresh blood samples
and PBMCs obtained after in vitro stimulation were car-
ried out according to methods previously described by
Giunchetti et al. [13]. The results were expressed as the
percentage of positive cells within the gated lymphocytes
for cell surface markers presenting bimodal distribution
(CD5, CD4, and CD8).
DNA Manipulations, Primers and Real Time PCR of spleen
Total genomic DNA was extracted from approximately 20
milligrams of spleen using Wizard™ Genomic DNA Purifi-
cation Kit (Promega®, Madison, WI, USA) following manu-
facturer’s recommendations. To quantify parasite burdens,
primers described by Bretagne et al. [36] to amplify a 90-bp
fragment of a single copy number gene of DNA polymerase
of L. infantum (GenBank accession number AF009147)
were used. PCR was carried out in a final volume of 25 μL
containing 200 nM forward and reverse primers, 1×SYBER
GREEN reaction master mix (Applied Biosystems, USA),
and 5 μL of template DNA. PCR conditions were as follows:
an initial denaturation step at 95°C for 10 min followed by
40 cycles of denaturation at 95°C for 15 s and annealing/
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for each run using known quantities of pGEM®T plasmids
(Promega®, Madison, WI, USA) containing inserts of inter-
est [37]. To verify the integrity of the samples, the same
procedure was carried out for the GAPDH gene (115-bp
fragment GenBank accession number AB038240). Reac-
tions were processed and analyzed in an ABI Prism 7500-
Sequence Detection System (Applied Biosystems, USA).
The results were expressed as the number of amastigotes
per milligram of spleen.
Statistical analysis
Statistical analyses were performed using Prism 5.0 soft-
































Figure 1 Anti-Leishmania reactivity in serum from dogs submitted to
challenge with L. infantum plus SGE: C (control; ); Sal (SGE; ); LBS
braziliensis vaccine plus saponin plus SGE; ). IgG2/IgG1 ratio: C (con
plus SGE; ). (A) anti–L. infantum total IgG; (B) anti–L. infantum IgG1; (C)
and LBSapSal (killed L. braziliensis vaccine plus saponin and SGE; black squa
(Tbc: time before challenge with L. infantum; and 20, 90, 274, 435, 541, and
the mean ELISA absorbance values determined at 492 nm in serum sample
by the dotted line. Significant differences (p < 0.05) between the LBSapSal
the letters a, b, and c. *Significant difference (p < 0.05) between the LBSapSof the data was detected using a Kolmogorov–Smirnoff test.
One-way analysis of variance and Tukey post-tests were
used to determine the differences between groups. In all
cases, the differences were considered significant when p
values were < 0.05.
Results
LBSapSal elicited lasting production of anti–L. infantum
immunoglobulin isotypes (IgG, IgG1, and IgG2) after L.
infantum experimental challenge
Significant (p < 0.05) increases in the serum levels of
anti-Leishmania total IgG at the time before challenge
(Tbc; i.e., 85 days before experimental challenge) and 20,




































Tbc 20 90 274 435 541 885
C
D
different vaccination protocols before and after intradermal
al (killed L. braziliensis vaccine plus SGE; ); LBSapSal (killed L.
trol; ) and LBSapSal (killed L. braziliensis vaccine plus saponin
anti–L. infantum IgG2; (D) IgG2/IgG1 ratio: C (control; white square)
re), the x-axis displays the times at which the assays were conducted
885 days after challenge with L. infantum), and the y-axis represents
s diluted 1:80 for IgG total and subclasses. The cut-off is represented
group and the C, Sal, and LBSal groups are indicated, respectively, by
al group and the control C group in IgG2/IgG1 ratio.
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Sal, and LBSal groups (Figure 1A). Also, the LBSapSal
group elicited higher levels (p < 0.05) of IgG1 at Tbc and
274, 541, and 885 dac compared with the other groups
(C, Sal, and LBSal). Moreover, the LBSapSal group
showed higher levels (p < 0.05) of IgG1 at 20 and 90 dac
compared with C and Sal groups (Figure 1B). Higher
levels (p < 0.05) of anti-Leishmania IgG2 were observed
in the LBSapSal group at Tbc and 20, 90, 274, and 885
dac compared with other groups (C, Sal, and LBSal)
(Figure 1C).
Further analysis demonstrated that the IgG2/IgG1 ra-
tio was lower (p < 0.05) in the LBSapSal group compared
with C (Tbc and 20, 90, 435, 541, and 885 dac), Sal (Tbc
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Figure 2 Cellular profile of circulating lymphocytes in dogs submitted
with L. infantum plus SGE. C (control; ); Sal (SGE; ); LBSal (killed L. bra
plus saponin plus SGE; ): the x-axis displays the times at which the assay
20, 90, 274, 435, 541, and 885 days after challenge [dac] with L. infantum), a
CD8+ cells, and (D) CD4+/CD8+ ratio, the white and black bars represented
(p < 0.05) between the LBSapSal group and the C, Sal, and LBSal groups are
difference (p < 0.05) between the LBSapSal group and the control C groupIncreased numbers of circulating T lymphocytes and their
subsets were displayed in LBSapSal-vaccinated dogs after
L. infantum experimental challenge
In order to evaluate the cellular immunophenotype pro-
file, we enumerated the frequency of T lymphocytes
(CD5+) and their major subpopulations (CD4+ and CD8+)
(Figure 2). Our results revealed an increase (p < 0.05) in
the number of circulating CD5+ T lymphocytes in dogs
vaccinated with LBSapSal group at 435 dac compared with
C and Sal groups and at 541 dac when compared with C,
Sal, and LBSal groups (Figure 2A).
Analyses of the data showed an increase (p < 0.05) of
circulating CD4+ T lymphocytes in the LBSapSal group
compared with the C and Sal groups at 435 dac and the
C, Sal, and LBSal groups at 541 dac (Figure 2B). In the
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to different vaccination protocols before and after challenge
ziliensis vaccine plus SGE; ); LBSapSal (killed L. braziliensis vaccine
s were conducted (Tbc: time before challenge with L. infantum; and
nd the y-axis represents the mean values of (A) CD5+, (B) CD4+, (C)
the control and LBSapSal groups, respectively. Significant differences
indicated, respectively, by the letters a, b, and c. *Significant
in CD4+/CD8+ ratio.
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pared with the C, Sal, and LBSal groups, at 90 and 274 dac
compared with the C and Sal groups, at 435 dac compared
with the Sal group, and at 541 and 885 dac in comparison
with all other groups (Figure 2C). Further analysis demon-
strated that the CD4+/CD8+ ratio was higher (p < 0.05) in
the LBSapSal group when compared with the C group at
541dac. On the other hand, at 885 dac, the CD4+/CD8+
ratio was lower (p < 0.05) in the LBSapSal group in com-
parison with the C group (Figure 2D).
In vitro cell proliferation upon antigenic stimuli is
persistently increased in LBSapSal-vaccinated dogs after
L. infantum experimental challenge
To explore the in vitro cell proliferation (PBMCs) we used
two different antigenic stimuli: VSA (L. braziliensis) in
order to evaluate the memory lymphoproliferative immune














90 435 885 90 435 885 90 435 885 90 435 885
Sal LBSal LBSapSal
a
























90 435 885 90 435 885 90 435 885 90 435 885
Sal LBSal LBSapSal C




Figure 3 Cell proliferation response of PBMCs after stimulation with (
antigen (SLiA). The lower panels show the immunophenotypic profile of
determined at 90, 435, and 885 dac (days after challenge with L. infantum
(killed Leishmania braziliensis vaccine plus SGE; ); LBSapSal (killed L. brazili
the ratio of mean frequencies of CD4+ and CD8+ cells in the stimulated cu
(p < 0.05) between values measured at 90, 435, and 885 dac under the sam
and the control C, Sal and LBSal groups are represented by the letters a, b,SLiA to investigate possible lymphoproliferative homology
with the etiological agent of VL (L. infantum) (Figure 3).
Comparative analysis of the different treatment groups
showed a significantly augmented (p < 0.05) stimulation
index at 885 dac in the LBSapSal dogs compared with the
C (885 dac) groups with VSA stimuli (Figure 3A). In
addition, the LBSapSal group exhibited a higher (p < 0.05)
lymphoproliferative index at 90 and 435 dac compared
with the C and LBSal dogs after SLiA stimuli (Figure 3B).
Higher frequencies of CD4+ and CD8+ T lymphocytes in
antigen-stimulated cultures related to major phenotypic
changes in LBSapSal-vaccinated dogs after L. infantum
experimental challenge
In order to evaluate whether the phenotypic profile of
PBMCs in vaccinated/challenged dogs was influenced by
VSA or SLiA stimulation, as well as to characterize these
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A) vaccine soluble antigen (VSA) and (B) soluble L. infantum
in vitro PBMCs following stimulation with (C) VSA and (D) SLiA
plus SGE) for vaccinated groups: C (control; ); Sal (SGE; ); LBSal
ensis vaccine plus saponin plus SGE; ). The results are expressed as
ltures over non-stimulated cultures (SC/CC). Significant differences
e group are indicated by connecting lines, and between the LBSapSal
and c, respectively.
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the presence of VSA (Figure 3C), a significant increase
(p < 0.05) in the stimulated cell/non-stimulated cell ra-
tio of CD8+ T cells was observed in the LBSapSal dogs
compared with the LBSal group at 90 dac. When we
evaluated the SLiA stimulus (Figure 3D), a significant
increase (p < 0.05) in the ratio of CD8+ T cells was ob-
served in the LBSapSal dogs at 90 and 435 dac com-
pared with 885 dac. In addition, the LBSapSal group
showed a higher (p < 0.05) ratio of CD8+ T lymphocytes
compared with the C dogs at 435 dac. In contrast, the
LBSapSal group displayed a significant decrease (p <
0.05) in the CD8+ T-cell ratio compared with the Sal
dogs at 885 dac.Splenic parasite burden is decreased in LBSapSal-
vaccinated dogs after L. infantum experimental challenge
The main parasitological features presented by all animals
are summarized in Figure 4. As shown in Figure 4, lower
(p < 0.05) numbers of amastigotes were observed in the
LBSapSal and LBSal groups compared with C dogs. These
data are associated with a parasite burden reduction of
60% in LBSal dogs, and 69% in the LBSapSal group com-
pared with C animals. These results indicate the high pro-
tective potential of the LBSapSal vaccine even for an





























Figure 4 Quantification of parasite burden in spleen samples at
885 dac (days after challenge with L. infantum plus SGE) for
vaccinated groups: C (control; ); Sal (SGE; ); LBSal (killed L.
braziliensis vaccine plus SGE; ); LBSapSal (killed L. braziliensis
vaccine plus saponin plus SGE; ). The y-axis displays the
quantification of amastigote forms of Leishmania per milligram of
spleen using real-time PCR with specific primers for a single-copy
gene of DNA polymerase of Leishmania infantum. The y-axis displays
inside the respective square of group the parasitism reduction (%) in
Sal, LBSal, and LBSapSal in comparison with the C group. Results
were plotted representing median values for each group. Significant
differences (p < 0.05) between the LBSapSal and LBSal groups
and the C group are represented by the letter a. C =mean 1657;
Sal = mean 823, reduction = 50%; LBSal = mean 667, reduction = 60%;
LBSapSal = mean 523, reduction = 69%.Discussion
The addition of sand fly saliva extract in vector-based
vaccines can enhance the ability of the host to control or
block the parasitic infection [38-41]. In this sense, our
study in dogs evaluated the immunogenicity and efficacy
of a vaccine composed of L. braziliensis crude antigens,
saponin as an adjuvant, and sand fly salivary gland ex-
tract (LBSapSal vaccine) 885 days after intradermal in-
oculation using L. infantum and SGE of Lu. longipalpis.
In a previous study, our group [14] demonstrated that
immunization with LBSapSal vaccine can induce high
levels of total IgG, IgG1, and IgG2 anti-Leishmania anti-
bodies. Interestingly, the present study demonstrated a
significant increase of these immunoglobulins 885 days
after experimental challenge. It has been proposed that
the serum reactivity observed in vaccinated dogs indi-
cates the antigen recognition of L. infantum, suggesting
the establishment of immunogenic events [13,14,32].
However, it is still not clear which subclass of immuno-
globulin would be associated with a CVL resistance pat-
tern. The increases in IgG1 and IgG2 subclasses appear
to characterize a mixed profile immune response, as pre-
viously described in dogs vaccinated with crude antigens
[6,13,14,42,43]. Moreover, there is controversy concerning
the association between IgG1 or IgG2 with a profile related
to resistance or susceptibility to infection in CVL [44].
Immunophenotyping of canine leukocytes by flow cy-
tometry has been used in an attempt to establish pat-
terns associated with the cellular profile linked to
resistance or susceptibility to infection by L. infantum
[3,45-48], beyond the immunogenic profile in anti-CVL
vaccine trials [13,14]. Our results revealed an increase in
the number of circulating CD5+ T lymphocytes in dogs
vaccinated with LBSal and LBSapSal. This increase was
associated with high levels of CD4+ T- and CD8+ T-
lymphocyte subpopulations. Interestingly, the LBSapSal
vaccine induced a persistent increase in CD8+ T lym-
phocytes throughout the period after challenge. In
immunophenotypic CVL studies, increases in CD5+ T
lymphocytes and subsets of CD4+ and CD8+ T lympho-
cytes were reported and related to a profile associated
with possible resistance against infection by L. infantum
[3,49-51]. In a Brazilian endemic area, vaccination of
dogs using Leishmune® was associated with increased
frequency of CD8+ T lymphocytes and an absence of
clinical signs 18 months after immunization [8]. The in-
crease in CD8+ T circulating lymphocytes in dogs vacci-
nated against CVL is considered to be an important
biomarker of resistance against infection by Leishmania
[13,14]. Thus, the expansion of CD5+ T lymphocytes
and the sustained increase of CD4+ and CD8+ T subsets
observed in LBSapSal vaccinated dogs seem to reflect
the attempt of the immune system to eradicate the para-
site after intradermal experimental challenge. This large
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cine probably induces responsive memory T lympho-
cytes, which expand in the peripheral blood inducing a
transient increase in CD5 and CD4 lymphocytes, due to
exposure to parasite in an attempt of the dogs' immune
system to control a possible increase or spread of the L.
infantum parasite to the organs.
To determine whether the LBSapSal vaccine would be
able to activate PBMCs under in vitro antigenic stimula-
tion with VSA and SLiA, we measured the stimulation
index at 90, 435, and 885 dac in cells derived from im-
munized dogs. The PBMCs of the Sal and LBSapSal
groups were able to recognize and respond to VSA,
showing increased stimulation index levels at 885dac
compared to the C group. This stimulation observed in
PBMC of Sal-vaccinated dogs indicates a nonspecific
stimulation and the use of SGE in the experimental chal-
lenge could stimulate the immune cells and occasional
oscillations occuring in these animals. Moreover, when
we stimulated PBMCs with SLiA, an increase in the
stimulation index was observed in the LBSapSal group
at 90 and 435 dac compared to the C dogs. Interestingly,
studies in dogs immunized with a bivalent vaccine com-
posed of crude antigens of Leishmania strains (L. ama-
zonensis and L. braziliensis) associated with BCG as the
adjuvant showed greater lymphoproliferative capacity in
response to stimulation with antigens of L. infantum
[15]. Furthermore, the ability to stimulate lymphoprolif-
erative activity using antigens of Leishmania has been
associated with an immune profile related to resistance
to CVL [47,49,50], supporting the hypothesis that the
LBSapSal vaccine induces a specific immune response
against the causative agent of CVL.
The analysis seeking to identify the phenotypic profile of
PBMC after in vitro stimulation (VSA or SLiA) showed an
increase in the stimulated ratio of CD8+ T lymphocytes in
the LBSal and LBSapSal groups in the presence of SLiA
compared to the C group. In fact, this result reflects the
expansion of circulating CD8+ T lymphocytes observed in
ex vivo analysis in the LBSapSal group. In addition, Reis
et al. [3] described high numbers of CD8+ T lymphocytes
from the spleens of asymptomatic dogs in the presence of
Leishmania antigen compared with symptomatic dogs, in-
dicating the importance of these cells to control the L.
infantum infection in dogs. In this sense, both in humans
and dogs, asymptomatic infection has been linked to
higher Leishmania-specific CD8+ T lymphocytes [52,53].
The data from the in vitro immunophenotypic profile
demonstrates a greater ability of the LBSapSal vaccine to
control parasites in dogs [3,47] and reflect improved con-
trol of tissue parasitism observed in vaccinated dogs. Thus,
the LBSapSal-vaccinated dogs showed a Leishmania-spe-
cific memory cell consistent with the ability to eliminate
parasites after the intradermal experimental challenge.In the context of the differences between experimental
and natural challenges, such as the number of parasites,
the life cycle stage (amastigote or promastigote), route of
infection, and presence or absence of vector saliva, are im-
portant variables that must be taken into account in experi-
mental challenges in the canine model. The experimental
challenge using an intravenous route with high numbers of
parasites (107–108 promastigotes) seems to be the most ef-
ficient challenge model [37]. However, this type of chal-
lenge can hide the real experimental vaccine efficacy by
suppressing a protective response that could be present in
vaccinated dogs [35,54-56]. Thus, an experimental model
of infection that most closely resembles Leishmania natural
transmission is increasingly recommended and desired by
many investigators; however, the use of infected sandflies is
not easy and remains an obstacle in the dog model. In this
work, we used SGE associated with the experimental chal-
lenge in an attempt to mimic a sand fly feeding on blood
and inoculating an animal with saliva and Leishmania pro-
mastigotes. However, our results showed that all dogs
remained asymptomatic throughout the follow-up (885
dac), indicating that the use of SGE was not sufficient to
replicate the bite environment and enhance experimental
infection [21-25].
In this study we selected the spleen as the target tissue
for detection of the parasite because it is naturally one
of the major sites for the parasites [46]. Further, the real-
time PCR technique, used by several authors in order to
diagnose and screen the evolution of VL in quantifying
the parasite burden, offers high sensitivity, accuracy, and
reproducibility [36,57,58]. In our work, we applied the
real-time PCR technique to quantify the number of
amastigotes per milligram of spleen. Interestingly, we
found that the LBSal group (60%) and LBSapSal dogs
(69%) had a higher proportion of parasite reduction
when compared with the control animals. This reduction
in parasite load may be associated with the immune re-
sponse induced by salivary components presenting in
both vaccines. Some studies show that Lu. longipalpis
salivary proteins induce an immune response associated
with protection in dogs [14,29]. Furthermore, in a ham-
ster model, salivary protein of a sand fly vector protects
against the fatal outcome of visceral leishmaniasis [28].
Thus, the protection obtained in the present study con-
firms the capacity of this prototype vaccine (LBSapSal)
to limit parasite replication even long after challenge
(885 days).
Conclusions
In the present study the LBSapSal vaccine offers great anti-
genic diversity with persistent humoral and cellular im-
mune responses being elicited, indicating a resistance
phenotype against CVL by induction of high levels of total
IgG (IgG1 and IgG2); expansion of circulating CD5+, CD4+,
Aguiar-Soares et al. Parasites & Vectors 2014, 7:61 Page 9 of 10
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tion of parasite load in spleen. The results presented in this
work encourage further study of vaccine strategies address-
ing Leishmania antigens in combination with proteins
present in the saliva of the vector.
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